Drugs / CAIV-T
CAIV-T
also known as
Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted · Influenza Virus Vaccine, Trivalent, Type A&B, Live, Cold-Adapted · Cold-adapted influenza vaccine trivalent · Influenza Virus Vaccine, Trivalent, Types A & B Live Cold-Adapted Liquid Formulation · Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) · influenza virus vaccine, trivalent, types A and B, live cold-adapted liquid · Trivalent Cold-Adapted Influenza Vaccine
Trials 20
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00192348 | May → Dec 2002 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT00192179 | Jun → Jul 2003 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT00192166 | Oct 2002 → Mar 2003 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT00192387 | Sep → Dec 2001 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT00192309 | Sep → Dec 2001 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT00192322 | Sep → Dec 2001 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT00192153 | Jul → Oct 2001 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT00192270 | Oct 2000 → Jan 2001 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 312 trials · 1 met primary | ||||||
| Phase 3 | NCT00128167 | Oct 2004 → Dec 2005 | influenza | MedImmune LLC | Completed | Met primary |
| Phase 3 | NCT00192205 | Oct 2002 → Jun 2003 | respiratory tract infectious disorder | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00192257 | Oct 2002 → May 2003 | asthma | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00192400 | Mar → Nov 2002 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00192374 | Feb → Nov 2002 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00192426 | Sep → Dec 2001 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00217230 | Apr → Nov 2001 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00192231 | Apr → Jun 2001 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00192192 | Nov → Dec 2000 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00192244 | Sep 2000 → Oct 2002 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00192283 | Sep 2000 → Apr 2002 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00192361 | Nov 1999 → ? | influenza | MedImmune LLC | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT00224783 Comparator | Aug → Sep 2002 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT00111579 Comparator | May 2005 → Jan 2006 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 3 | NCT00192335 Comparator | Jul 2004 → Feb 2005 | — | MedImmune LLC | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAIV-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00192179 ↗ |
| Known as | Cold-adapted influenza vaccine trivalent | “Cold-adapted influenza vaccine trivalent (CAIV-T)” NCT00192179 ↗ |
| Known as | Influenza Virus Vaccine, Trivalent, Type A&B, Live, Cold-Adapted | “Influenza Virus Vaccine, Trivalent, Type A&B, Live, Cold-Adapted (CAIV-T)” NCT00192257 ↗1“Influenza Virus Vaccine, Trivalent, Type A&B, Live, Cold-Adapted (CAIV-T)” NCT00192205 ↗ |
| Known as | Influenza Virus Vaccine, Trivalent, Types A & B Live Cold-Adapted Liquid Formulation | “Influenza Virus Vaccine, Trivalent, Types A & B Live Cold-Adapted Liquid Formulation (CAIV-T)” NCT00192179 ↗ |
| Known as | Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted | “A Randomized, Double-Blind Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted...” NCT00192361 ↗2“A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted...” NCT00192348 ↗ “Influenza Virus Vaccine, Trivalent, Types A & B,Live, Cold-Adapted (CAIV-T)” NCT00192374 ↗ |
| Known as | Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) | “Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T)” NCT00192244 ↗ |
| Known as | influenza virus vaccine, trivalent, types A and B, live cold-adapted liquid | “influenza virus vaccine, trivalent, types A and B, live cold-adapted liquid (CAIV-T)” NCT00192348 ↗ |
| Known as | Trivalent Cold-Adapted Influenza Vaccine | “Trivalent Cold-Adapted Influenza Vaccine (CAIV-T)” NCT00111579 ↗ |
| Modality | Vaccine | “Trivalent Cold-Adapted Influenza Vaccine” NCT00111579 ↗ |
| Route | Intranasal | “will be administered intranasally” NCT00111579 ↗ |